Axsome Therapeutics Inc. recently announced receiving a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for AXS-14, intended for managing fibromyalgia. The FDA found the application incomplete, specifically citing inadequacies in one of the two placebo-controlled trials due to its 8-week primary endpoint and flexible-dose paradigm. In response, Axsome plans to conduct an additional controlled trial with a fixed-dose paradigm and a 12-week primary endpoint, as requested by the FDA, and aims to initiate this trial in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.